Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.5%

1 terminated/withdrawn out of 67 trials

Success Rate

96.0%

+9.5% vs industry average

Late-Stage Pipeline

13%

9 trials in Phase 3/4

Results Transparency

0 of 24 completed trials have results

Key Signals

18 recruiting

Enrollment Performance

Analytics

Phase 1

29(43.3%)

Phase 2

27(40.3%)

Phase 3

9(13.4%)

N/A

2(3.0%)

67Total

Phase 1(29)

Phase 2(27)

Phase 3(9)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (67)

Showing 20 of 67 trials

NCT07040072Phase 1Recruiting

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Role: collaborator

NCT06769555Not ApplicableWithdrawn

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Role: collaborator

NCT07166211Phase 2Recruiting

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Role: lead

NCT07519577Phase 2Not Yet Recruiting

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）

Role: lead

NCT07292688Phase 1Recruiting

Study of CM383 in Healthy Subjects

Role: lead

NCT07175493Phase 1Recruiting

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

Role: lead

NCT07039578Phase 2Recruiting

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Role: lead

NCT07019779Phase 1Recruiting

Study of CM518D1 in Patients With Advanced Solid Tumors

Role: lead

NCT07230483Phase 2Recruiting

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

Role: lead

NCT06495229Phase 3Active Not Recruiting

Study of CM310 in Adolescent Subjects With Atopic Dermatis

Role: lead

NCT06277765Phase 3Completed

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

Role: lead

NCT07175506Phase 1Recruiting

Study of CM559 in Healthy Subjects

Role: lead

NCT06553209Phase 1Completed

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis

Role: lead

NCT06830395Phase 2Not Yet Recruiting

Study of CM313 in Subject With IgA Nephropathy

Role: lead

NCT07181239Phase 3Not Yet Recruiting

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Role: lead

NCT07011524Phase 2Recruiting

Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

Role: lead

NCT06947980Phase 2Recruiting

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT06792019Phase 1Recruiting

Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness

Role: lead

NCT07106372Phase 3Not Yet Recruiting

A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Role: lead

NCT06424470Phase 3Active Not Recruiting

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Role: lead